Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Clover Biopharmaceuticals Ltd
2197Current price
0.32 HKD
+0.00000000039 HKD (+0.00%)
Last closed
0.32 HKD
Company
www.cloverbiopharma.com
ISIN
KYG2280A1076
Sector
Healthcare
Industry
Biotechnology
Exchange
Hong Kong Stock Exchange
Capitalization
395 623 639 HKD
Yield for 12 month
-59.09 %
1Y
3Y
5Y
10Y
15Y
2197
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research and development, manufacture, and commercialization of vaccines in Mainland China. Its product candidates include SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine; AdimFlu-S (QIS), a quadrivalent split inactivated vaccine for the treatment of influenza A and B; SCB-219M, a thrombopoietin receptor agonist mimetic bispecific Fc-fusion protein to treat cancer patients with chemotherapy-induced thrombocytopenia; and SCB-313, an oncology product candidate for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis. The company is also developing SCB-2023B for COVID-19 treatment; SCB-1019, a product development platform for the creation of protein-based vaccines based on naturally trimerization-dependent targets; and SCB-1001 for rabies treatment. In addition, it provides consulting services and sells biopharmaceutical drugs. The company was founded in 2007 and is headquartered in Shanghai, the People's Republic of China. Address: No. 758 West Nanjing Road, Shanghai, China
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
30.42 HKDP/E ratio
–Dividend Yield
–Current Year
+42 352 896 HKD
Last Year
–
Current Quarter
+277 282 HKD
Last Quarter
–
Current Year
+26 154 029 HKD
Last Year
–
Current Quarter
+59 342 HKD
Last Quarter
–
Key Figures 2197
1 year
3 years
5 years
10 years
EBITDA
-956 187 694 HKD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-25.5 %
PEG Ratio
–
Return On Equity TTM
-648.53 %
Wall Street Target Price
30.42 HKD
Revenue TTM
28 916 650 HKD
Book Value
-0.64 HKD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
-475 949 962 HKD
Earnings per share
–
Diluted Eps TTM
–
Most Recent Quarter
II 2023
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics 2197
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 2197
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 2197
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
25.974
Enterprise Value Revenue
3.4343
Price Sales TTM
13.6815
Enterprise Value EBITDA
0.0261
Price Book MRQ
11.722
Financials 2197
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 2197
For 52 weeks
0.2 HKD
0.79 HKD
50 Day MA
0.3 HKD
Shares Short Prior Month
–
200 Day MA
0.36 HKD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart